<DOC>
	<DOCNO>NCT01278160</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare effect glycaemic control biphasic insulin aspart 30 twice daily two different dosage split regimens Chinese subject type 2 diabetes achieve treatment target glycosylated haemoglobin A1c ( HbA1c ) 7 % trial BIASP-3756 ( NCT01123980 ) .</brief_summary>
	<brief_title>Comparison Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens Subjects With Type 2 Diabetes : An Extension Trial BIASP-3756</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Finalised 24 week treatment daily BIAsp 30 insulin glargine combination metformin glimepiride trial BIAsp3756 HbA1c equal 7.0 % Body Mass Index ( BMI ) equal 40.0 kg/m2 Known hypoglycaemia unawareness recurrent major hypoglycaemic episode trial BIAsp3756 Known proliferative retinopathy maculopathy require acute treatment Any disease condition Investigator ( trial physician ) feel would interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>